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abstract
PURPOSE To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a
gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal
patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer.
PATIENTS AND METHODS Premenopausal women with stage cT2 to 4b, any N, M0; estrogen receptor and
progesterone receptor greater than 50%; human epidermal growth factor receptor 2–negative breast cancer
were randomly assigned to triptorelin 3.75 mg administered intramuscularly on day 1 of every cycle or degarelix
240 mg administered subcutaneously (SC) on day 1 of cycle 1 then 80 mg SC on day 1 of cycles 2 through 6,
both with letrozole 2.5 mg/day for six 28-day cycles. Surgery was performed 2 to 3 weeks after the last injection.
Serum was collected at baseline, after 24 and 72 hours, at 7 and 14 days, and then before injections on cycles 2
through 6. The primary end point was time to optimal OFS (time from the ﬁrst injection to ﬁrst assessment of
centrally assessed estradiol level # 2.72 pg/mL [# 10 pmol/L] during neoadjuvant therapy). The trial had 90%
power to detect a difference using a log-rank test with a two-sided a of .05. Secondary end points included
response, tolerability, and patient-reported endocrine symptoms.
RESULTS Between February 2014 and January 2017, 51 patients were enrolled (n = 26 received triptorelin plus
letrozole; n = 25 received degarelix plus letrozole). Time to optimal OFS was three times faster for patients
assigned to degarelix and letrozole than to triptorelin and letrozole (median, 3 v 14 days; hazard ratio, 3.05; 95%
CI, 1.65 to 5.65; P , .001). Furthermore, OFS was maintained during subsequent cycles for all patients
assigned to receive degarelix and letrozole, whereas 15.4% of patients assigned to receive triptorelin and
letrozole had suboptimal OFS after cycle 1 (six events during 127 measurements). Adverse events as a result of
both degarelix plus letrozole and triptorelin plus letrozole were as expected.
CONCLUSION In premenopausal women receiving letrozole for neoadjuvant endocrine therapy, OFS was
achieved more quickly and maintained more effectively with degarelix than with triptorelin.
J Clin Oncol 37. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Ovarian function suppression (OFS) was the ﬁrst form
of systemic treatment for advanced breast cancer.1 Its
use as an adjuvant therapy was associated with im-
proved disease-free and overall survivals in patients
younger than age 50 years who had breast cancer.2
Currently, for premenopausal patients with endocrine-
responsive breast cancer, OFS is considered an im-
portant aspect of treatment in the advanced disease3
setting and in the adjuvant and neoadjuvant settings.4
Gonadotropin-releasing hormone (GnRH) analogs in-
teract with the GnRH receptor and modify release of
pituitary gonadotropins. Several GnRHanalogs have been
developed (eg, triptorelin, goserelin and leuprolide), and
there are no apparent differences in their OFS capabil-
ities.5 Upon administration of GnRH agonists, an initial
stimulating action of the hypophysis occurs (ﬂare effect),
which eventually causes a sustained decrease in go-
nadotropin secretion (downregulation) that can be ob-
served after approximately 10 days. For some patients,
there can be a delay of 2 to 4months until downregulation
of the gonadotropins occurs. Moreover, approximately
20%ofwomendo notmaintain complete OFSwithGnRH
analogs6 and experience occasional elevations in estradiol
(E2) as a result of sporadic escapes from OFS.
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Degarelix (Firmagon; Ferring, Copenhagen, DK) is a GnRH
antagonist that binds to and blocks GnRH receptors in the
pituitary gland, which results in decreased secretion of
gonadotropins. In men, this leads directly to a rapid de-
crease in the production of testosterone, for which sup-
pression to castration levels is achieved within 1 to 3 days
and remains sustained during treatment.7,8 Degarelix is
currently approved for the treatment of prostate cancer.
Data are not available for the use of degarelix in patients
with breast cancer.
In premenopausal women, suppression of ovarian function
with degarelix might be faster than with GnRH analogs and
optimally maintained throughout the treatment period.
Neoadjuvant endocrine therapy (NET) is an excellent
platform for the development of investigational drugs and
the exploration of novel combinations that can be de-
veloped in other clinical settings.9
Limited data are available on NET in premenopausal pa-
tients. In the Neoadjuvant Anastrozole Versus Tamoxifen in
Patients Receiving Goserelin for Premenopausal Breast
Cancer (STAGE) trial, 204 premenopausal women were
randomly assigned to receive goserelin 3.6 mg/month plus
either anastrozole or tamoxifen for 24 weeks before surgery.
More patients in the anastrozole group than in the ta-
moxifen group had a complete or partial response (70.4% v
50.5%, respectively).10
We therefore designed the TREND (Trial on the Endocrine
activity of Neoadjuvant Degarelix) trial (International Breast
Cancer Study Group [IBCSG] 41-13), an open-label, two-
arm, phase II, randomized study, to compare the endocrine
activity of triptorelin versus degarelix in premenopausal
patients with breast cancer receiving letrozole as NET.
PATIENTS AND METHODS
Patients
Premenopausal women with histologically conﬁrmed stage
cT2 to 4b, any nodal stage, M0; estrogen (ER) and pro-
gesterone (PgR) receptor expression greater than 50%;
human epidermal growth factor receptor 2 (HER2)–neg-
ative (by immunohistochemistry and/or in situ hybridiza-
tion); invasive breast cancer were eligible. Premenopausal
status was determined locally as 17-b-estradiol (ie, E2)
levels greater than 54 pg/mL (or . 198 pmol/L) measured
within 14 days before random assignment. Patients could
not have had a prior GnRH analog, a selective ER mod-
ulator or aromatase inhibitor (AI) within 12 months before
random assignment, or used hormonal treatment (eg,
oral, injectable, implanted contraceptive or medicated
intrauterine device) in the 2 months before random
assignment.
Study Design
Patients were randomly assigned in a 1:1 ratio to receive six
28-day cycles of NET with one of the following: triptorelin
3.75 mg intramuscularly on day 1 of every cycle plus
letrozole 2.5 mg/day orally; or degarelix 240 mg sub-
cutaneously given as two subcutaneous injections of
120 mg on day 1 of cycle 1 followed by 80 mg on day 1 of
cycles 2 through 6 plus letrozole. Letrozole was started on
day 1, concurrent with triptorelin or degarelix. Trial treat-
ments were to start within 14 days of random assignment
and could be started at any time during the menstrual
cycle. Deﬁnitive surgery was performed within 2 to 3 weeks
after the last administration of triptorelin or degarelix. After
postsurgery evaluation, no additional follow-up data were
collected within the trial. Postsurgical treatments were
given at the discretion of the investigator. Random as-
signment was stratiﬁed according to age at random as-
signment (# 39 v $ 40 years).
Study visits occurred before every 28-day cycle for
6 months and required a physical exam, an Eastern Co-
operative Oncology Group performance status, weight, and
collection of adverse events (AEs; 31 targeted AEs and
other grades 3 to 4 AEs according to Common Terminology
Criteria for AEs, version 4.0). Tumor evaluation by bilateral
mammography and breast ultrasound and laboratory tests
(hematology, chemistry, carcinoembryonic antigen [CEA],
cancer antigen 15.3 [CA15.3]) were required at baseline,
after three cycles, and before surgery. Data about AEs and
concomitant medications were also collected 30 days after
surgery. Patients completed the 19-item Functional As-
sessment of Cancer Therapy, endocrine subscale (FACT-
ES) at baseline, on day 1 of cycles 2 and 4, and before
surgery.
E2, follicle-stimulating hormone (FSH), and luteinizing
hormone (LH) levels were determined in a central labo-
ratory from serum samples collected at day 1 of the ﬁrst
treatment cycle before the administration of the ﬁrst dose
(baseline), at 24 and 72 hours, 7 days and 14 days after ﬁrst
injection, and on day 1 of cycles 2 through 6. E2 con-
centrations were measured by gas chromatography tan-
dem mass spectrometry detection after liquid-liquid
extraction. Duplicate standard curves, water blanks, and
four assay control pools were processed with samples to
assess accuracy and precision of the assay. The lower limit
of E2 level quantiﬁcation was 0.625 pg/mL. Central pa-
thology review of diagnostic biopsy and of the residual
surgical specimen was mandatory for this trial, but patients
were included on the basis of tumor characteristics as
determined by the local pathologist.
The primary end point was time to optimal OFS, calculated
as the time from the ﬁrst injection of degarelix or triptorelin
until the ﬁrst occurrence of a centrally assessed E2 level in
the range of optimal OFS (# 2.72 pg/mL or# 10 pmol/L)11
during the six cycles of NET. Secondary end points in-
cluded best overall response according to WHO response
criteria,12 rate of node-negative disease at surgery, rate of
breast-conserving surgery (BCS), preoperative endocrine
prognostic index (PEPI) score, Ki-67 (protein encoded by
2 © 2018 by American Society of Clinical Oncology
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the MKI67 gene) changes, and patient-reported endocrine
symptoms (by FACT-ES summary score).13
The trial was conducted in three centers in Italy. The IBCSG
coordinated the trial and is responsible for the study design,
random assignment, collection and management of data,
medical review, data analysis, and reporting. The trial was
conducted in accordance with the provisions of the Dec-
laration of Helsinki. The ethics committees at each center
approved the study protocol, and all patients provided
written informed consent. The IBCSG Data and Safety
Monitoring Committee reviewed the trial twice yearly.
Ferring donated the study drugs.
Statistical Considerations
Analyses were performed according to the intention-to-treat
principle. Kaplan-Meier estimates of the cumulative pro-
portions of patients who achieved optimal OFS were cal-
culated. Cox proportional hazards regression and the log-
rank test, stratiﬁed according to age, were used to estimate
the hazard ratio, 95%CI, and P value in a comparison of the
time to optimal OFS between the two treatment groups.
The statistical design assumed that the cumulative per-
centages of patients with optimal OFS by 2, 4, 8, 12, and
16 weeks were 30%, 60%, 75%, 90%, and 100% of pa-
tients, respectively, assigned to triptorelin plus letrozole and
60%, 95%, 100%, 100%, and 100% of patients, re-
spectively, assigned to degarelix plus letrozole. With 23
patients per group, the study had 90% power to detect a
between-group difference in time to optimal OFS using a two-
sample log-rank test (two-sided a = .05). The calculations
were performed using nQuery Advisor (Statistical Solutions
Ltd. 8 South Bank Crosse’s Green Cork, Ireland) for the log-
rank test of survival in two groups (simulation with the
aforementioned percentages speciﬁed). To allow for missing
data, the study planned enrollment of 50 patients.
Secondary end points were summarized as the number
and percentage of patients or as the median (interquartile
range [IQR]) of values by treatment group and/or as
between-group differences, and data were reported with
CIs. Changes in Ki-67 between pretreatment biopsy and
post-treatment surgery were assessed within and between
groups using Wilcoxon signed-rank and rank-sum tests,
respectively. The analysis of differences in patient-reported
FACT-ES summary scores (range, 0 to 76; higher score
indicated better function) between treatment groups used
linear mixed-effects modeling as a function of postbaseline
timepoint and treatment group and controlled for the
stratiﬁcation factors of age (dichotomized as # 39 v $ 40
years) and baseline summary score with an autoregressive
covariance structure. For each symptom, the proportion of
patients who reported a clinically signiﬁcant symptom level
(responses of “quite a bit’’ or ‘‘very much’’ a problem)14 at
one or more postbaseline time points was summarized with
90% CIs. The analysis used SAS 9.4 (SAS Institute, Cary,
NC), and R version 3.3.1.
RESULTS
Study Population
Between February 24, 2014, and January 10, 2017, 51
patients with ER-positive and PgR-positive (ER and PgR
. 50%), HER2-negative, invasive breast cancer were randomly
assigned (n = 26 assigned to triptorelin plus letrozole; n = 25
assigned to degarelix plus letrozole; Fig 1). The median age
of the patients was 44 years (IQR, 42 to 49 years; Table 1). All
patients had an Eastern Cooperative Oncology Group per-
formance status of 0, 49% had clinically node-positive dis-
ease, and 90% had a ductal histology.
All patients started and completed six cycles of the assigned
trial treatment, with the exception of one patient randomly
assigned to degarelix plus letrozole who had surgery after
three cycles because of progressive disease. Compliance
regarding blood draws over time for the enrolled patients was
excellent: 502 (99%) of the 507 blood draws required to
assess OFS status over time were obtained.
Endocrine Activity
By the end of the ﬁrst cycle (29 days), all patients reached
optimal OFS. OFS was reached signiﬁcantly faster among
patients assigned to degarelix plus letrozole than among
those assigned to triptorelin plus letrozole (median, 3 v
14 days, respectively; hazard ratio, 3.05); optimal OFS was
achieved three times faster with degarelix plus letrozole
than with triptorelin plus letrozole (95% CI, 1.65 to 5.65;
P , .001; Fig 2). Notably, optimal OFS was maintained for
all patients assigned degarelix plus letrozole during sub-
sequent cycles, whereas 15.4% of patients assigned trip-
torelin plus letrozole had suboptimal OFS (E2 level . 2.72
pg/mL) after cycle 1 (0 events with 119 measurements and
six events with 127 measurements, respectively; Fig 3;
Appendix Table A1, online only; Appendix Fig A1, online
Trial 41-13: TREND
Randomly assigned
(N = 51)
Triptorelin + letrozole
(n = 26)
Degarelix + letrozole
(n = 25)
Treatment
Initiated and completed
  neoadjuvant therapy       (n = 26)
Had surgery performed     (n = 26) 
Treatment
Initiated and completed
  neoadjuvant therapy        (n = 25) 
Had surgery performed     (n = 23)
Analyzed
ITT population                     (n = 26)
Safety population               (n = 26)
Surgery population            (n = 26) 
Analyzed
ITT population                  (n = 25)
Safety population                (n = 25)
Surgery population             (n = 23) 
FIG 1. TREND (Trial on the Endocrine Activity of Neoadjuvant
Degarelix) CONSORT diagram. ITT, intention to treat.
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TABLE 1. Patient and Pretreatment Disease Characteristics According to Treatment Assignment
Characteristic
Treatment Assignment
Total
(N = 51)Triptorelin + Letrozole (n = 26) Degarelix + Letrozole (n = 25)
Age, years
Median (IQR) 44 (42-48) 45 (42-50) 44 (42-49)
Range 31.0-51.0 26.0-55.0 26.0-55.0
# 39 4 (15.4) 2 (8.0) 6 (11.8)
$ 40 22 (84.6) 23 (92.0) 45 (88.2)
Body-mass index, kg/m2
Normal (, 25) 15 (57.7) 14 (56.0) 29 (56.9)
Overweight or obese ($ 25) 8 (30.8) 8 (32.0) 16 (31.4)
Unknown 3 (11.5) 3 (12.0) 6 (11.8)
Prior oral contraceptive use 8 (30.8) 7 (28.0) 15 (29.4)
Smoking status
Current 2 (7.7) 5 (20.0) 7 (13.7)
Former 3 (11.5) 2 (8.0) 5 (9.8)
Never 21 (80.8) 18 (72.0) 39 (76.5)
E2, pg/mL (assessed centrally)
Median (IQR) 86 (57-131) 98 (70-194) 94 (65-163)
Range 21.6-250.0 37.8-404.0 21.6-404.0
Histology of biopsy (assessed centrally)
Ductal 24 (92.3) 22 (88.0) 46 (90.2)
Lobular 1 (3.8) 2 (8.0) 3 (5.9)
Other/unknown 1 (3.8) 1 (4.0) 2 (3.9)
Clinical T stage (by ultrasound)
T2 24 (96.0) 19 (79.2) 43 (87.8)
T3 1 (4.0) 5 (20.8) 6 (12.2)
Unknown/missing 1 1 2
Clinical N stage
N0 12 (46.2) 14 (56.0) 26 (51.0)
N1 13 (50.0) 10 (40.0) 23 (45.1)
N2-N3 1 (3.8) 1 (4.0) 2 (4.0)
ER status of biopsy
Positive (ER . 50%) 26 (100.0) 25 (100.0) 51 (100.0)
PR status of biopsy
Negative (PgR # 50%) 1 (3.8) 0 (0.0) 1 (2.0)
HER2 status of biopsy
Negative 26 (100.0) 25 (100.0) 51 (100.0)
Median (IQR) Ki-67 labeling index, % staining cells of
biopsy*
20 (12-30) 16 (14-28) 17 (12-29)
Median (IQR) FACT-ES summary score 69 (64-75) 70 (66-73) 70 (66-74)
NOTE. Data are presented as No. (%) unless otherwise speciﬁed.
Abbreviations: E2, estradiol; ER, estrogen receptor; FACT-ES, functional assessment of cancer therapy, endocrine subscale; HER2, human epidermal
growth factor receptor 2; IQR, interquartile range; Ki-67, protein encoded by the MKI67 gene; PgR, progesterone receptor.
*Ki-67 was determined in a central laboratory.
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only. FSH and LH over time are summarized in Figure 4 and
Appendix Figures A2, A3, and A4 (online only).
Surgery and Pathology
Forty-nine patients underwent surgery after completion of
NET; two patients decided to seek alternative therapies and
did not receive surgery within the protocol-suggested time
frame. Overall, 38.8% of patients had node-negative dis-
ease at surgery (Table 2). Node-negative disease rates were
43.5% versus 34.6% for degarelix plus letrozole versus
triptorelin plus letrozole, and the estimated absolute
difference was 8.9% (90% CI, 214.0% to 31.8%). Like-
wise, BCS rates were 52.2% versus 42.3% for degarelix
plus letrozole versus triptorelin plus letrozole, and the
absolute difference was 9.9% (90%CI,213.5% to 33.3%).
Thirty percent of patients (9 of 30 patients) considered
candidates for mastectomy received BCS; 74% of those
considered candidates for BCS at baseline (14 of 19 pa-
tients) underwent BCS, whereas the remaining 26% (ﬁve of
19 patients) underwent mastectomy.
The median PEPI score at surgery was 6 (IQR, 4 to 7); only
one patient (2.0%) had a PEPI score of 0. Ki-67 expression
levels were available for all patients on the diagnostic biopsy
and for 47 on surgery (excision) samples. Signiﬁcant re-
ductions in Ki-67 from baseline to surgery were detected
within each treatment group (Appendix Fig A5, online
only). Median changes were 210.0% (90% CI, 213.5%
to25.5%; P = .001) for degarelix plus letrozole and29.5%
(90% CI, 215.0% to 26.0%; P =.005) for triptorelin plus
letrozole. The changes were not different between the two
treatment groups (P = .55).
Overall, 45.1% of patients had partial responses and
47.1% had stable disease as best overall response. Ob-
jective response rates were 44.0% versus 46.2% for
degarelix plus letrozole versus triptorelin plus letrozole
(difference, 22.2%; 90% CI, 225.1% to 20.8%). For
patients treated with NET, pathologic complete response is
less frequent and not the appropriate surrogate of treatment
beneﬁt, so it was not a prespeciﬁed end point in the trial. We
observed only one pathologic complete response in a
patient treated with degarelix plus letrozole.
AEs
There were no treatment-related grade 4 AEs in either
treatment group, and there were only two grade 3 AEs
(hypertension and anemia) in two patients assigned to
triptorelin plus letrozole (Table 3). The most common AEs
with degarelix plus letrozole versus triptorelin plus letrozole
were hot ﬂashes (80.0% v 69.2%), arthralgia (32.0% v
53.8%), insomnia (24.0% v 11.5%), injection site reaction
(24.0% v 0%), hypertension (12.0% v 3.8%), and nausea
(16.0% v 3.8%).
Patient-Reported Endocrine Symptoms
The FACT-ES completion rates were 88% across assess-
ment time points and were similar between treatment
groups. Patients assigned to degarelix plus letrozole re-
ported worse FACT-ES summary scores at each post-
baseline time point (Appendix Fig A6, online only)
compared with patients assigned to triptorelin plus letro-
zole. The most burdensome symptoms were hot ﬂashes:
40.0% of patients who received degarelix plus letrozole and
30.8% of patients who received triptorelin plus letrozole
reported clinically signiﬁcant levels (Appendix Table A2,
online only). Similar proportions in each group were in-
dicated for night sweats. Clinically signiﬁcant mood swings
were noted in 32.0% of patients who received degarelix
plus letrozole and in 11.5% of patients who received
triptorelin plus letrozole. Feeling irritable and joint pains
were reported by 24.0% (for each AE) of the degarelix-
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plus-letrozole group and by 11.5% and 15.4%, respec-
tively, of the triptorelin-plus-letrozole group.
DISCUSSION
The results of the TREND trial indicate that, in pre-
menopausal patients treated with letrozole as NET for
endocrine-responsive breast cancer, degarelix acted faster
than triptorelin to induce optimal OFS. Moreover, degarelix
ensured maintenance of optimal OFS in all patients during
the subsequent (cycles 2 through 6) treatment period,
whereas 15.4% of patients assigned to triptorelin plus
letrozole had suboptimal OFS during NET.
These results are consistent with reports of degarelix activity
in prostate cancer.7 In two phase II dose-ﬁnding clinical
trials, degarelix 240/160 mg and 240/80 mg were shown to
effectively suppress testosterone levels in patients with
prostate cancer without testosterone surge or inducement
of clinical ﬂare.15,16 In another trial, both 240/160 mg and
240/80 mg doses were effective and noninferior to leu-
prolide 7.5 mg in suppression of testosterone.8
The maintenance of optimal OFS during degarelix therapy
might have signiﬁcant clinical value in the treatment of
premenopausal patients with breast cancer not only in the
neoadjuvant setting but also in the adjuvant and metastatic
settings. In the adjuvant setting, two recently published
clinical trials led to a paradigm shift in the endocrine
treatment of premenopausal women. The joint analysis of
the SOFT (Suppression of Ovarian Function Trial) and TEXT
(Tamoxifen and Exemestane Trial) trials showed that the
combination of OFS plus exemestane signiﬁcantly re-
duced recurrence compared with OFS plus tamoxifen.17
The combination of OFS plus exemestane is currently
recommended for patients at intermediate/high risk of
relapse together with adjuvant chemotherapy.4,18
Bellet et al19 reported that, during the ﬁrst year of
exemestane plus triptorelin in the SOFT trial, 17% of the
patients had E2 levels greater than the threshold of 2.72 pg/mL
(10 pmol/L). Baseline factors related to E2 level greater
than 2.72 pg/mL were no prior chemotherapy (P = .06),
higher BMI (P= .05), and lower FSH and LH (eachP, .01).19
Other authors reported that approximately 20% of women
do not reach complete OFS with LH-releasing hor-
mone analogs plus AIs.6 This is consistent with our study,
in which 15.4% of the patients did not maintain OFS during
triptorelin treatment. In our trial, the median age was similar
to that described in the SOFT and TEXT trials, but most
patients were older than age 40 years and therefore less
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FIG 3. Estradiol (E2; pg/mL) proﬁle over
time of 51 patients according to treat-
ment assignment. The x-axis corre-
sponds to blood draw time (in days)
before (A) triptorelin or (B) degarelix
injections (0 = before cycle 1 injection;
days 29, 57, 85, 113, and 141 = before
cycles 2 through 6 injections, respec-
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FIG 4. (A) Follicle-stimulating hormone (FSH; IU/L) and
(B) luteinizing hormone (LH; IU/L) proﬁles over time for
51 patients according to treatment assignment. The
x-axis corresponds to blood draw time (in days) before
triptorelin or degarelix injections (0 = before cycle 1
injection; days 29, 57, 85, 113, and 141 = before cycles
2 through 6 injections, respectively). The blood draw
time scale was adjusted to show the data points in cycle
1 as well as the subsequent cycles in the same ﬁgure.
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likely to have ovarian breakthroughs than were younger
patients, who showed the greatest beneﬁt from the associ-
ation of OFS and exemestane in the SOFT and TEXT trials.
One could speculate that, in a younger cohort, degarelix
could have translated to an even higher percentage of
maintained OFS compared with triptorelin. In the presence
of incomplete OFS by GnRH analogs, treatment with AIs can
stimulate the residual ovarian function and lead to an in-
crease in plasma estrogen levels.11 Guidelines for the use of
adjuvant AIs recommend caution when E2 levels deter-
mined by highly sensitive/speciﬁc methods such as gas
chromatography tandem mass spectrometry detection are
more than 10 pmol/L (. 2.72 pg/mL) during treatment with
AIs, because this indicates that AIs are not exerting full
effectiveness.11
To our knowledge, this is the ﬁrst report on the use of
degarelix in the treatment of women with breast cancer.
The toxicity proﬁle of degarelix was as expected, and no
safety signals were identiﬁed. Most commonly reported AEs
were related to E2 deprivation. The maximum toxicity grade
was 2, with the exception of two grade 3 AEs (hypertension
and anemia) in two patients assigned to triptorelin plus
letrozole. A considerable proportion of patients experienced
clinically signiﬁcant symptom burdens, and higher pro-
portions occurred in patients who received degarelix plus
letrozole. The open nature of this study may have affected
the AE reports by patients. On the written trial information, a
very common ($ 10%) prevalence of hot ﬂushes and in-
jection site AEs was reported for degarelix. Although it is not
known how these issues were addressed in the discussion
with the patients, it is unlikely that such an effect may
explain the different proﬁles of the patient-reported
symptoms. Patients should be made aware of lifestyle in-
terventions and integrative therapies to minimize AEs from
endocrine treatment.20
In this analysis, higher node-negative disease rates and
higher BCS rates were observed for patients assigned to
degarelix plus letrozole versus triptorelin plus letrozole.
These data compare well with results from the literature. In
a cohort of premenopausal patients treated with NET, the
overall response rate was 50%.21
Potential limitations of this study are the small number of
patients enrolled and the lack of postsurgery follow-up,
which did not allow conclusions about the difference in
disease outcomes between the treatment groups. In
addition, at the time of study design, few similar data were
available for breast cancer. The design assumptions of the
cumulative optimal OFS rates with triptorelin at time points
were based on studies from prostate cancer,8,22 and the
assumptions appeared to be different from those actually
observed. Even so, the comparison depends only on rank
data (log-rank test), so the study still has good power to
detect a relative difference between treatment arms.
Strengths of our study are adherence to protocol re-
quirements (all patients initiated and completed protocol
NET), compliance to trial treatments (most patients re-
ceived triptorelin/degarelix injections during the hospital
visits), and central assessment of E2 levels. The study is
TABLE 2. Surgical Pathology Characteristics According to Treatment Assignment
Characteristic
Treatment Assignment
Total
(N = 49)
Triptorelin + Letrozole
(n = 26)
Degarelix + Letrozole
(n = 23)
Pathologic T stage
T0 0 (0.0) 1 (4.3) 1 (2.0)
T1 8 (30.8) 5 (21.7) 13 (26.5)
T2 12 (46.2) 13 (56.5) 25 (51.0)
T3 6 (23.1) 4 (17.4) 10 (20.4)
Pathologic N stage
N0 9 (34.6) 10 (43.5) 19 (38.8)
N1 9 (34.6) 9 (39.1) 18 (36.7)
N2 4 (15.4) 1 (4.3) 5 (10.2)
N3 4 (15.4) 3 (13.0) 7 (14.3)
Median (IQR) Ki-67 labeling index (% staining cells)* 5 (3-17) 8 (4-14) 6 (3-16)
Median (IQR) PEPI score (of 0-12 scale) 6.5 (4-7) 6 (4-7) 6 (4-7)
PEPI score of 0 0 (0.0) 1 (4.3) 1 (2.0)
pCR 0 (0.0) 1 (4.3) 1 (2.0)
NOTE. Data are presented as No. (%) of patients unless otherwise speciﬁed.
Abbreviations: IQR, interquartile range; Ki-67, protein encoded by the MKI67 gene; pCR, pathologic complete response; PEPI, preoperative endocrine
prognostic index.
*Ki-67 was determined in a central laboratory.
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hypothesis generating and supports larger studies to assess
whether maintenance of OFS with degarelix translates into
a better clinical outcome and is worth a trade-off of in-
creased rate of some AEs. Ongoing clinical trials about NET
in premenopausal patients are investigating novel associ-
ations,20 and will help identify the best candidates for such
treatment as well as possible ways to optimize treatment
efﬁcacy.
In conclusion, in premenopausal women receiving letrozole
for primary treatment of endocrine-responsive breast
cancer, OFS was achieved more quickly and maintained
more effectively with degarelix than with triptorelin
throughout the NET period. These data support additional
studies to assess whether degarelix improves disease
control compared with the current standard of care in the
treatment of premenopausal patients with breast cancer.
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TABLE 3. Patients with Grades 1 to 4 and Grades 3 to 4 Targeted AEs and Other Grades 3 and 4 AEs Reported
AE by CTCAE version 4
AEs by Treatment Assignment and Grade
Triptorelin + Letrozole (n = 26) Degarelix + Letrozole (n = 25)
Grade 1-4 Grade 3-4 Grade 1-4 Grade 3-4
Hot ﬂashes/ﬂushes 69.2 (51.3 to 83.7) 80.0 (62.5 to 91.8)
Arthralgia 53.8 (36.2 to 70.8) 32.0 (17.0 to 50.4)
Insomnia 11.5 (3.2 to 27.2) 24.0 (11.0 to 42.0)
Injection site reaction 0 24.0 (11.0 to 42.0)
Nausea 3.8 (0.2 to 17.0) 16.0 (5.7 to 33.0)
Hypertension 3.8 (0.2 to 17.0) 3.8 (0.2 to 17.0) 12.0 (3.4 to 28.2)
Fatigue 11.5 (3.2 to 27.2) 4.0 (0.2 to 17.6)
Anxiety 7.7 (1.4 to 22.3) 8.0 (1.4 to 23.1)
Depression 3.8 (0.2 to 17.0) 8.0 (1.4 to 23.1)
Myalgia 7.7 (1.4 to 22.3) 4.0 (0.2 to 17.6)
Vaginal dryness 3.8 (0.2 to 17.0) 4.0 (0.2 to 17.6)
ALT increase 3.8 (0.2 to 17.0) 0
Other grades 3 and 4 AEs* 3.8 (0.2 to 17.0) 3.8 (0.2 to 17.0) 0
NOTE. Data are presented as % (90% exact binomial CI). Thirty-one selected AEs, as well as other AEs of grade 3 or greater, were captured on the case
report form. Only those with at least one reported event are tabulated.
Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events.
*The other nontargeted grade 3 AE was anemia.
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FIG A1. Distributions of estradiol (E2) levels over time according to treatment assignment. (A) Days 0 to 14 of cycle 1;
(B) days 29 to 141 (before injection at cycles 2 to 6). The gray line corresponds to E2 threshold of 2.72 pg/mL.
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FIG A2. Distributions of follicle-stimulating hormone (FSH) levels over time according to treatment assignment. (A)
Days 0 to 14 of cycle 1; (B) days 29 to 141 (before injection at cycles 2 to 6).
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FIG A3. Distributions of luteinizing hormone (LH) levels over time according to treatment assignment. (A) Days 0 to 14
of cycle 1; (B) days 29 to 141 (prior to injection at cycles 2 to 6).
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FIG A4. Correlation of (A) follicle-stimulating hormone (FSH) and (B) luteinizing hormone (LH) levels with estradiol
(E2) status (E2# 2.72 pg/mL to reach ovarian function suppression [OFS] v E2 . 2.72 pg/mL for suboptimal OFS)
over time.
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FIG A5. Ki67 (protein encoded by the MIK67 gene) labeling index (%) at baseline (pre-treatment biopsy) and at surgery (residual disease). (A) Distributions
of Ki67 according to time point and treatment assignment. (B) Changes in Ki67 between time points for individual participants, overall and according to
treatment assignment.
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FIG A6. Functional assessment of cancer therapy, endocrine subscale
(FACT-ES), summary scores (range, 0 to 76; higher score denotes better
functioning) at baseline and during neoadjuvant endocrine therapy.
FACT-ES was completed before the ﬁrst injection and on day 1 of cycles 2 and
4 as well as before surgery. Plots are the adjusted means with 90% CIs.
TABLE A1. Percentage of Patients’ E2 Levels # 2.72 pg/mL During Time Points of the First Cycle According to Treatment Assignment
Variable
Blood Draw Time (days since ﬁrst injection)
0 1 3 7 14 29*
Corresponding treatment cycle Baseline C1 d1 C1 d3 C1 d7 C1 d14 C2 d1
Triptorelin + letrozole
No. with E2 measurement 26 26 24 26 25 25
No. (%) with E2 # 2.72 pg/mL 0 (0) 0 (0) 0 (0) 9 (35) 20 (80) 25 (100)
Degarelix + letrozole
No. with E2 measurement 25 25 24 24 25 25
No. (%) with E2 # 2.72 pg/mL 0 (0) 4 (16) 20 (83) 22 (92) 22 (88) 25 (100)
Abbreviation: E2, estradiol; C, cycle; d, day.
*Blood draw was before C2 injection.
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TABLE A2. Percentage of Patients Who Experienced Clinically Signiﬁcant FACT-ES Individual Item Score at Any Time During Neoadjuvant Treatment by
Treatment Assignment
FACT-ES Item
Treatment Assignment
Difference
(D + L minus T + L)
Triptorelin + Letrozole
(n = 26)
Degarelix + Letrozole
(n = 25)
Hot ﬂashes 30.8 (15.9 to 45.7) 40.0 (23.9 to 56.1) 9.2 (212.7 to 31.2)
Cold sweats 7.7 (0.0 to 16.3) 12.0 (1.3 to 22.7) 4.3 (29.4 to 18.0)
Night sweats 26.9 (12.6 to 41.2) 40.0 (23.9 to 56.1) 13.1 (28.5 to 34.6)
Vaginal discharge 3.8 (0.0 to 10.0) 0.0 (0.0 to 0.0) 23.8 (210.0 to 2.4)
Vaginal irritation 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0)
Vaginal bleeding 7.7 (0.0 to 16.3) 0.0 (0.0 to 0.0) 27.7 (216.3 to 0.9)
Vaginal dryness 3.8 (0.0 to 10.0) 8.0 (0.0 to 16.9) 4.2 (26.7 to 15.0)
Pain or discomfort with intercourse 7.7 (0.0 to 16.3) 12.0 (1.3 to 22.7) 4.3 (29.4 to 18.0)
Lost interest in sex 7.7 (0.0 to 16.3) 12.0 (1.3 to 22.7) 4.3 (29.4 to 18.0)
Gained weight 3.8 (0.0 to 10.0) 0.0 (0.0 to 0.0) 23.8 (210.0 to 2.4)
Light-headed (dizzy) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0)
Vomiting 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0)
Diarrhea 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0)
Headaches 7.7 (0.0 to 16.3) 12.0 (1.3 to 22.7) 4.3 (29.4 to 18.0)
Bloated feeling 3.8 (0.0 to 10.0) 8.0 (0.0 to 16.9) 4.2 (26.7 to 15.0)
Breast tenderness 3.8 (0.0 to 10.0) 16.0 (3.9 to 28.1) 12.2 (21.4 to 25.7)
Mood swings 11.5 (1.2 to 21.8) 32.0 (16.7 to 47.3) 20.5 (2.0 to 38.9)
Feeling irritable 11.5 (1.2 to 21.8) 24.0 (10.0 to 38.0) 12.5 (25.0 to 29.9)
Joint pains 15.4 (3.7 to 27.0) 24.0 (10.0 to 38.0) 8.6 (29.6 to 26.9)
NOTE. Percentages are reported as No. (90% CI). Item scores were “quite a bit” or “very much” a problem.
Abbreviation: FACT-ES, functional assessment of cancer therapy, endocrine subscale.
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